Skip to Content
Morningstar

Lexicon Pharmaceuticals Inc LXRX Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis LXRX

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics LXRX

More

Company Profile LXRX

Business Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Contact
2445 Technology Forest Boulevard, 11th Floor
The Woodlands, TX, 77381
T +1 281 863-3000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 87

Related News LXRX

Stock Analyst Update

Slashing Fair Value Estimate on Lexicon Pharmaceuticals

Sotagliflozin's side effects and competitor data lead to a near $10 cut.
Karen Andersen
Stock Analyst Update

Lexicon: On Its Way to Building Competitive Advantages

Our bullish view on potential sales of the first drug of this development-stage biotech is balanced by the expected ramp-up in operating expenses in 2017.
Karen Andersen
ETF Specialist

How to Be Smarter About Risk Management

Investors should only take risks that the market rewards--and that they can live with.
Alex Bryan
ETF Specialist

How to Be Smarter About Risk Management

Investors should only take risks that the market rewards--and that they can live with.
Alex Bryan
Stock Strategist Industry Reports

The Next Wave of Blockbuster Diabetes Drugs

New diabetes drugs offer blockbuster potential for drug companies.
Damien Conover
US Videos

Lexicon an Attractive Takeover Candidate

The small-cap biotech firm's experimental diabetes drug could make it a M&A target says Morningstar's Karen Anderson.
Erik Kobayashi-Solomon
US Videos

Our Top Five Biotech Takeout Picks

Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
Karen Andersen
US Videos

Will 'Knockout' Mice Make a Knockout Stock?

After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?
Erik Kobayashi-Solomon
Our Picks

Four Firecracker Stocks

These high-risk/high-reward plays could add spark to your portfolio, but investors must handle them with caution.
Jeremy Glaser
Stock Analyst Update

Four Stocks with High-Return Potential

Why the market's got it wrong on these 5-star names.
Jeffrey Ptak
Stock Analyst Update

Bargains Sprout Up as Market Dips

20 firms hit 5 stars amid recent downturn.
Jeffrey Ptak
Stock Strategist

Five Firms Big Pharma Should Buy Next

With acquisitions slated to continue, here's a look at the possibilities.
Karen Andersen